$1.96
+0.13 (+7.10%)
Performance
1D
—
1W
—
1M
+10.11%
3M
+6.52%
6M
-52.66%
1Y
-52.66%
YTD
-52.66%
Open$1.87
Previous Close$1.83
Day High$1.99
Day Low$1.87
52W High$6.18
52W Low$1.07
Volume—
Avg Volume1.17M
Market Cap118.23M
P/E Ratio—
EPS$-0.46
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$1.68
Above
RSI (14)
47.8
Neutral
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2,103.1% upside
Current
$1.96
$1.96
Target
$43.18
$43.18
$31.72
$43.18 avg
$59.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 34.78M | 32.14M | 39.05M |
| Net Income | 5.77M | 7.01M | 8.10M |
| Profit Margin | 16.6% | 21.8% | 20.7% |
| EBITDA | 11.08M | 11.55M | 13.91M |
| Free Cash Flow | 4.11M | 3.56M | 7.02M |
| Rev Growth | +3.0% | +6.5% | +17.8% |
| Debt/Equity | 0.16 | 0.15 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |